Reslizumab (Cinqaero®)

Assessment Status Rapid Review Complete
Drug Reslizumab
Brand Cinqaero®
Indication Is indicated as add-on therapy in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus another medicinal product for maintenance treatment.
Assessment Process
Rapid review commissioned 23/01/2017
Rapid review completed 01/03/2017
Rapid review outcome Full Pharmacoeconomic Evaluation Recommended at the submitted price.

The HSE has approved reimbursement following confidential price negotiations April 2019.